Journal of Capital Medical University ›› 2010, Vol. 31 ›› Issue (5): 563-565.

• 慢性乙肝临床转归个体化治疗预测模型研究 • Previous Articles     Next Articles

Two year Efficacy of Entecavir for the Treatment of Chronic Hepatitis B, Compensated and Decompensated Cirrhosis

YOU Hong*, WU Xiao-ning, WANG Qian-yi, WU Peng, CONG Rui, YANG Ai-ting, OU Xiao-juan, MA Hong, ZHANG Fu-kui, WANG Bao-en, JIA Ji-dong
  

  1. Liver Research Center, Beijing Friendship Hospital, Capital Medical University
  • Received:1900-01-01 Revised:1900-01-01 Online:2010-10-21 Published:2010-10-21
  • Contact: YOU Hong

PDF

713

Abstract: Objective To compare antiviral effects of entecavir in patients with chronic hepatitis B, compensated and decompensated cirrhosis patients after 2 years of treatment with entecavir. Methods Totally 63 treatment-na-ve patients with chronic hepatitis B(41 cases), compensated(15 cases) and decompensated cirrhosis(7 cases) patients were treated with entecavir 0.5 mg once daily. Alanine aminotransferase(ALT) and HBV DNA were detected and analyzed at three-month interval. Results The baseline characteristics of the three groups were comparable by age, gender, ALT and HBV DNA. There was no significant difference in ALT normalization and HBeAg seroconversion rate after oneyear and twoyear entecavir treatment. The 2-year HBV DNA undetectable(<5×105 IU/mL) rate and median reductions were 81.8% and 5.4 lg in chronic hepatitis B, 83.3% and 6.0 lg in compensated cirrhosis, 88.1% and 5.8 lg in decompensated cirrhosis. The kinetics of HBV DNA suppression at every 3 months interval were similar among three groups. Conclusion There was no significant difference efficacy of after 2 years of treatment with entecavir in patients with chronic hepatitis B, compensated and decompensated cirrhosis patients.

Key words: entecavir, chronic hepatitis B, liver cirrhosis

CLC Number: